We just covered the 10 Best Non-AI Stocks to Buy According to Billionaire Stanley Druckenmiller. NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) ranks #5 (see 5 Best Non-AI Stocks to Buy According to Billionaire Stanley Druckenmiller).
Druckenmiller's Stake: $98,275,000
Druckenmiller likes asymmetric bets where he can risk a small position for potentially large upside. NAMS falls in this category. It's a Netherlands-based biotech developing obicetrapib, an oral drug designed to lower bad cholesterol. The product is targeted towards people who are not able to reach target levels even after taking standard treatments like statins.
A lot of patients with cardiovascular disease or high cholesterol are still not able to reach LDL targets even with existing therapies, which creates a large unmet medical need for an easy-to-take oral option.
If approved, it could become a widely used add-on therapy with global demand; if it fails in key outcome trials or regulatory review, the downside is significant because there is little diversification in the pipeline.
Druckenmiller's Stake: $98,275,000
Druckenmiller likes asymmetric bets where he can risk a small position for potentially large upside. NAMS falls in this category. It's a Netherlands-based biotech developing obicetrapib, an oral drug designed to lower bad cholesterol. The product is targeted towards people who are not able to reach target levels even after taking standard treatments like statins.
A lot of patients with cardiovascular disease or high cholesterol are still not able to reach LDL targets even with existing therapies, which creates a large unmet medical need for an easy-to-take oral option.
If approved, it could become a widely used add-on therapy with global demand; if it fails in key outcome trials or regulatory review, the downside is significant because there is little diversification in the pipeline.
2 months ago
